Integration of multiview microbiome data for deciphering microbiome-metabolome-disease pathways

arXiv:2402.08222 · stat.ME · Submitted 2024-02-13 · Read on arXiv

Listen

Radio episode about this paper

Transcript

Introduction to the show: ident: Statistics. The day in statistics: methods, theory and the inference under them.

Tom: I'm Tom.

Jane: And I'm Jane, here with Lu, Meng and our in-house large language model, Lalam.

Tom: We're looking at the paper: "Integration of multiview microbiome data for deciphering microbiome-metabolome-disease pathways".

Jane: Here's the gist of the paper. The study introduces an integrative framework to establish microbiome-metabolome-disease pathways by leveraging multiview microbiome data and an external cohort to mitigate hidden confounders This method supports the identification of disease-specific and microbiome-associated metabolites that are missing in the target cohort.

Tom: Model Framework and Pathway Delineation The authors first introduce a structural equation model to delineate the pathways connecting the microbiome, metabolome, and disease processes utilizing a target multiview microbiome data The proposed linear structural equation models (1) and (2) provide insights into the microbiome-metabolome-disease pathway as shown in Fig.

Tom: The model parameters define four categories for the microbes based on their coefficients in (β∗) and (γ∗).

Paper summary: Tom: We're talking about the paper "Integration of multiview microbiome data for deciphering microbiome-metabolome-disease pathways" here. They introduce this two-stage system that uses both a target study and an external cohort to figure out how microbes, metabolites, and disease processes are connected.

Jane: It sounds like they're tackling the problem that just looking at one dataset doesn't give you the whole picture when mapping these complex biological pathways in the body. What exactly is their main argument?

Lu: They start by setting up a structural equation model using the target multiview microbiome data to define those initial pathways between microbes, metabolites, and disease outcomes <ref:2402.08222#pg1>.

Meng: That sounds like a solid starting point for defining the baseline structure of the system. But then they seem to run into a problem with just using that target data alone <ref:2402.08222#pg2>.

Meng: That’s how they get metabolite values for the target study using that external information. But then there's this point about removing a limitation there. They eliminate the need for that external study to include the disease outcome of interest <ref:2402.08222#pg3>.

Jane: So what’s their goal with all this extra work? It seems like they want to find metabolites that are relevant even if they aren't clearly linked in their main study <ref:2402.08222#pg2>.

Lu: They aim to identify disease-specific and microbiome-associated metabolites that might be missing from the original target cohort <ref:2402.08222#pg1>.

Conclusion: Tom: So we're wrapping up this look at "Integration of multiview microbiome data for deciphering microbiome-metabolome-disease pathways." Basically, they developed a two-stage system to connect microbes, metabolites, and disease processes using data from both a target study and an external cohort.

Jane: Right. The authors are showing that relying only on one dataset doesn't give you the full story when mapping these complex pathways in the body. They use an external study to fill in those gaps where their main group is missing information about metabolites or microbes.

Lu: They first set up structural equation models using their target data to define the initial pathway structure, categorizing microbes into four groups based on how they link to outcomes and metabolites.

Meng: Then they introduce this two-stage approach where you train a prediction model on that external data and plug those predictions back into the main pathway model. That’s how they get metabolite values for the target study.

Tom: It’s about using what you know from one place to improve what you don't know in another, and they even removed the need for that external study to have disease outcome data. That makes it way more flexible for people trying to use these models.

Jane: So, when we look at the title again, "Integration of multiview microbiome data," it really highlights that mixing different kinds of data sources—microbes, metabolites—is what unlocks a better picture of how things happen in the body.

Lu: It’s about building a more robust framework for finding those disease-specific metabolites that might be hidden in the original dataset. They even have simulation studies showing that their method handles those hidden confounders better than just using the target data alone

Lei Fang, Yue Wang, Chenglong Ye

University of Minnesota · University of Colorado Anschutz Medical Campus · University of Kentucky

stat.ME

Submitted: 2024-02-13

Updated: 2026-10-27

DOI: 10.1093/bioinformatics/btag787

License: http://creativecommons.org/licenses/by/4.0/

Importance score: 77/100

The gist: The study introduces an integrative framework to establish microbiome-metabolome-disease pathways by leveraging multiview microbiome data and an external cohort to mitigate hidden confounders This…

Key concepts

Structural Equation Model (SEM)
This statistical tool is used to map out the complex relationships between three different biological layers: the microbiome, metabolites, and disease outcomes. It helps researchers visualize and test hypothesized pathways connecting these elements.
Multiview Microbiome Data
This refers to using multiple perspectives or datasets of microbial information. By combining different views of the microbiome, the study aims to get a more complete picture of how microbes influence biological processes like metabolism and disease.
External Cohort Integration
The method supplements the main study's data by using an independent, external dataset. This integration is used to predict missing or low-quality metabolite information, making the pathway analysis more robust and generalizable beyond the initial study.

Terminology

Summary

The study introduces an integrative framework to establish microbiome-metabolome-disease pathways by leveraging multiview microbiome data and an external cohort to mitigate hidden confounders This method supports the identification of disease-specific and microbiome-associated metabolites that are missing in the target cohort. p. 0

Where the paper says it

To mitigate the challenges posed by hidden confounders, we further propose an integrative approach that incorporates data from an external microbiome cohort. This method also supports the identification of disease-specific and microbiome-associated metabolites that are missing in the target cohort.

Model Framework and Pathway Delineation

The authors first introduce a structural equation model to delineate the pathways connecting the microbiome, metabolome, and disease processes utilizing a target multiview microbiome data The proposed linear structural equation models (1) and (2) provide insights into the microbiome-metabolome-disease pathway as shown in Fig. 1. The model parameters define four categories for the microbes based on their coefficients in (β∗) and (γ∗). p. 1

Where the paper says it

Indeed, our first contribution is a high-dimensional structural equation model for detecting microbiome-metabolome-disease pathways using a single multiview microbiome cohort, referred to as the target-only method hereafter. The model parameters define four categories for the microbes, each representing a distinct function that microbes play in the pathway.

p. 1
Where the paper says it

Indeed, our first contribution is a high-dimensional structural equation model for detecting microbiome-metabolome-disease pathways using a single multiview microbiome cohort, referred to as the target-only method hereafter. The model parameters define four categories for the microbes, each representing a distinct function that microbes play in the pathway.

p. 1
Where the paper says it

Indeed, our first contribution is a high-dimensional structural equation model for detecting microbiome-metabolome-disease pathways using a single multiview microbiome cohort, referred to as the target-only method hereafter. The model parameters define four categories for the microbes, each representing a distinct function that microbes play in the pathway.

These categories are defined as G1, G2, G3, and G4 based on whether microbes are associated with both the outcome and metabolites or only one of them. p. 3
Where the paper says it

Letting A = {1, . , p} index all p microbes, we can categorize the microbes into the following four groups based on the coefficients of β ∗ and γ ∗ : • G1 = {l ∈ A | β ∗ l ̸= 0 and γ ∗ l ̸= 0}: microbes in G1 are associated with both the outcome and metabolites.

p. 3
Where the paper says it

Letting A = {1, . , p} index all p microbes, we can categorize the microbes into the following four groups based on the coefficients of β ∗ and γ ∗ : • G1 = {l ∈ A | β ∗ l ̸= 0 and γ ∗ l ̸= 0}: microbes in G1 are associated with both the outcome and metabolites.

p. 3
Where the paper says it

Letting A = {1, . , p} index all p microbes, we can categorize the microbes into the following four groups based on the coefficients of β ∗ and γ ∗ : • G1 = {l ∈ A | β ∗ l ̸= 0 and γ ∗ l ̸= 0}: microbes in G1 are associated with both the outcome and metabolites.

Mitigating Confounding via Integration

The second contribution navigates around the limitations of the target-only method by integrating an external multiview microbiome study to supplement metabolites that are either missing or of insufficient quality within the target study. This two-stage procedure involves first training a prediction model for the metabolite using the external study and then fitting the structural equation model with predicted values. p. 2

Where the paper says it

We develop a two-stage estimation and inference approach. We first train a prediction model for the metabolite of interest using the external study.

p. 2
Where the paper says it

We develop a two-stage estimation and inference approach. We first train a prediction model for the metabolite of interest using the external study.

The requirement for the external study to include the disease outcome is eliminated, which enhances flexibility and broad applicability. p. 4
Where the paper says it

Secondly, the necessity for the external study to include the disease outcome is obviated, allowing for the utilization of data from a diverse array of sources. This feature significantly enhances the flexibility and broad applicability of our proposed integrative method.

Inference and Hypothesis Testing

The authors develop a debiased Lasso estimator of θ∗ defined in (10) to test H0: θ∗ = 0 by decomposing it into noise and bias components. Corollary 1 suggests that by leveraging an external data set and using the twostage procedure discussed above, an asymptotically valid p-value for testing H0 is attainable by de-biasing. p. 7

Where the paper says it

, Cov(εi , δi) ̸= 0). In contrast, Corollary 1 suggests that by leveraging an external data set and using the twostage procedure discussed above, an asymptotically valid p-value for testing H0 is attainable by de-biasing.

This approach suggests that for target-only scenario, one can first randomly split this target dataset into two parts to guarantee the validity of the inference. p. 7
Where the paper says it

In contrast, Corollary 1 suggests that by leveraging an external data set and using the twostage procedure discussed above, an asymptotically valid p-value for testing H0 is attainable by de-biasing. This further suggests that for target-only scenario, we can first randomly split this target dataset into two parts, one serving as the new target data, and the other serving as the external cohort.

Validation through Simulation

Data-driven simulation studies demonstrate the performance of the proposed estimation and inference procedures across various scenarios. The simulations show that when latent confounders exist (ρ = 0. p. 2

Where the paper says it

Significantly, the requirement for the external study to include the disease outcome of interest is eliminated, simplifying the acquisition of suitable external datasets. This methodology not only enhances the robustness of the findings by mitigating the risks associated with latent confounders and incomplete metabolite profiles but also expands the scope of analysis through the utilization of broader metabolomic data.

25), the target-only method suffers from a highly inflated type-I error rate, whereas the integrative method maintains a well-controlled type-I error rate and decent power. p. 0
Where the paper says it

keywords: data integration, debiased lasso, hidden confounder, high dimensional inference 1 Introduction The human gut microbes play a crucial role in maintaining our health and well-being by aiding in digestion, immune system regulation, and synthesizing essential nutrients (Flint et al. For example, dysbiosis, an imbalance or disruption in the microbiome, has been associated with various diseases, including inflammatory bowel disease (IBD), obesity, allergic disorders, Type 1 diabetes, autism, obesity, and colorectal cancer (DeGruttola 1 arXiv:2402.

Furthermore, the simulation results indicate that when external data is partially informative (τ > 1), the proposed method becomes unreliable indicated by either high type I error or low power. p. 8
Where the paper says it

Thus, since the proposed integrative procedure can efficiently account for hidden confounders, the p-value defined in (14) may be used to identify metabolites that causally impact the disease outcome. 4 Partially informative external dataset All theoretical results established in Section 2.

Real-World Application and Insights

In the real data application, integrating iHMP and FRAN data improved statistical power and biological relevance for metabolites that were microbially regulated in the FRAN cohort. The analysis identified 8 metabolites that showed different results between the target-only method and the integrative method, suggesting that any external cohort may be informative regarding a subset of metabolites but not for all of them. p. 0

Where the paper says it

To mitigate the challenges posed by hidden confounders, we further propose an integrative approach that incorporates data from an external microbiome cohort. This method also supports the identification of disease-specific and microbiome-associated metabolites that are missing in the target cohort.

The framework also characterizes the roles that individual microbes play in the detected pathways, providing an explanation for specific microbe-IBD links. p. 1
Where the paper says it

Also, they focus on assessing the pairwise relationships among microbiome, metabolome, and disease, lacking a comprehensive understanding of the roles that metabolites play in the microbiome-disease link. Therefore, there is an urgent need to develop an integrative framework to establish microbiome-metabolome-disease pathways by leveraging existing multiview microbiome data.

Future Directions

The authors suggest extending the linear model to some mixture model that can simultaneously handle missing data and skewed metabolomics data. The framework also has connections with transcriptome-wide association studies (TWAS), suggesting a potential path to adjust for microbes’ direct effects on the phenotype. p. 3

Where the paper says it

The proposed structural equation models (1) and (2) provide insights into the microbiome-metabolome-disease pathway, as shown in Fig. Specifically, θ ∗ represents the host-metabolome association after controlling for the effects of the microbes.

The current framework analyzes each metabolite at a time, and extending it to simultaneously analyze multiple metabolites in the same metabolic pathway is suggested as an interesting future direction. p. 4
Where the paper says it

2 Integrative model for target and external microbiome studies In this section, we address the hidden confounding issue by extending the target-only method to an integrative approach that leverages an external microbiome cohort. The main idea is to first predict the metabolite of interest using the external study and then infer the microbiome-metabolome-disease pathway based on the predicted values.

Pruning redundant reasoning tokens

The paper first proposes a target-only method to integrate microbiome, metabolites, and disease outcomes to identify relevant microbiome-metabolome-disease pathways The proposed linear structural equation models (1) and (2) provide insights into the microbiome-metabolome-disease pathway as shown in Fig. 1. The model parameters define four categories for the microbes based on their coefficients in (β∗) and (γ∗). These categories are defined as G1, G2, G3, and G4 based on whether microbes are associated with both the outcome and metabolites or only one of them.

How the training signal is built

The second contribution navigates around the limitations of the target-only method by integrating an external multiview microbiome study to supplement metabolites that are either missing or of insufficient quality within the target study. This two-stage procedure involves first training a prediction model for the metabolite using the external study and then fitting the structural equation model with predicted values.

Where the gains come from

The authors develop a data-driven procedure to quantify such informativeness by calculating predictive correlation between Xγb and Xebγe as an indicator of the external dataset's informativeness. This predictive correlation remains around 0. p. 9

Where the paper says it

Furthermore, if the target study lacks the metabolite of interest, we may find an alternative metabolite that is highly correlated with the one of interest and observed in both studies. We then develop a data-driven method, called the “predictive correlation”, to examine the informativeness of the external cohort based on this highly correlated metabolite.

p. 9
Where the paper says it

Furthermore, if the target study lacks the metabolite of interest, we may find an alternative metabolite that is highly correlated with the one of interest and observed in both studies. We then develop a data-driven method, called the “predictive correlation”, to examine the informativeness of the external cohort based on this highly correlated metabolite.

8 when τ < 1, suggesting that the external dataset is informative for a subset of metabolites. p. 8
Where the paper says it

Thus, since the proposed integrative procedure can efficiently account for hidden confounders, the p-value defined in (14) may be used to identify metabolites that causally impact the disease outcome. 4 Partially informative external dataset All theoretical results established in Section 2.

p. 8
Where the paper says it

Thus, since the proposed integrative procedure can efficiently account for hidden confounders, the p-value defined in (14) may be used to identify metabolites that causally impact the disease outcome. 4 Partially informative external dataset All theoretical results established in Section 2.

The proposed framework can be easily extended to include observed covariates due to the flexibility of l-1 penalized models. p. 4
Where the paper says it

Secondly, the necessity for the external study to include the disease outcome is obviated, allowing for the utilization of data from a diverse array of sources. This feature significantly enhances the flexibility and broad applicability of our proposed integrative method.

The authors first propose a target-only method to integrate microbiome, metabolites, and disease outcomes to identify relevant microbiome-metabolome-disease pathways The proposed linear structural equation models (1) and (2) provide insights into the microbiome-metabolome-disease pathway as shown in Fig. 1. The model parameters define four categories for the microbes based on their coefficients in (β∗) and (γ∗). These categories are defined as G1, G2, G3, and G4 based on whether microbes are associated with both the outcome and metabolites or only one of them.

The authors develop a data-driven procedure to quantify such informativeness by calculating predictive correlation between Xγb and Xebγe as an indicator of the external dataset's informativeness. This predictive correlation remains around 0.8 when τ < 1, suggesting that the external dataset is informative for a subset of metabolites.

Green — the paper says it, and the page is printed. Red — no passage carries it, so treat that sentence as unverified. The same check runs on your own text: check a summary against its source, $5.

Improvements for AI systems

  1. Data integration for disease pathway discovery: The improved AI system can integrate multiview microbiome data with external cohorts to identify microbiome-metabolome-disease pathways, specifically by using a two-stage estimation procedure that supplements metabolites that are either missing or of insufficient quality within the target study.

  2. Hidden confounder mitigation: The system can account for hidden confounders by modeling the relationship between error terms as correlated, utilizing an extension of the framework where observed covariates are included to characterize the causal effect of mi on yi.

  3. Causal inference for metabolites: The improved system can identify metabolites that causally impact disease outcomes by leveraging the integrative procedure's ability to account for both observed and hidden confounders, allowing it to define a p-value based on the decomposition of the estimated effect.

  4. Variable selection consistency: By incorporating thresholding procedures, the system can achieve consistent variable selection with an additional thresholding step to identify groups G1 through G4, which delineate microbes based on their association with both outcome and metabolites.

  5. Partially informative data utilization: The AI system can quantify the informativeness of external datasets using a predictive correlation, allowing it to determine if an external cohort is informative for specific metabolites by calculating the correlation between estimated coefficients Xgamma b and Xeb gamma e.

Abstract

The intricate interplay between host organisms and their gut microbiota has catalyzed research into the microbiome's role in disease, shedding light on novel aspects of disease pathogenesis. However, the mechanisms through which the microbiome exerts its influence on disease remain largely unclear. In this study, we first introduce a structural equation model to delineate the pathways connecting the microbiome, metabolome, and disease processes, utilizing a target multiview microbiome data. To mitigate the challenges posed by hidden confounders, we further propose an integrative approach that incorporates data from an external microbiome cohort. This method also supports the identification of disease-specific and microbiome-associated metabolites that are missing in the target cohort. We provide theoretical underpinnings for the estimations derived from our integrative approach, demonstrating estimation consistency and asymptotic normality. The effectiveness of our methodologies is validated through comprehensive simulation studies and an empirical application to inflammatory bowel disease, highlighting their potential to unravel the complex relationships between the microbiome, metabolome, and disease.

Sources

Related papers